Bausch + Lomb reports Phase 2 findings for BL1332 in post-surgical ocular pain
BLCO•Bausch + Lomb said BL1332 doses showed greater pain relief than vehicle, but the study did not meet its primary endpoint of improving pain intensity over 24 hours.
BLCO•Bausch + Lomb said BL1332 doses showed greater pain relief than vehicle, but the study did not meet its primary endpoint of improving pain intensity over 24 hours.
Bausch + Lomb reported that BL1332 doses showed greater pain relief than vehicle in a study of post-surgical ocular pain, but the study did not meet its primary endpoint of pain intensity improvement over 24 hours. The company reported no treatment-related or serious adverse events and said the results support FDA discussions on future development and Phase 3 planning.